hVEGF-IN-1 ol-7-O-β-D-glucopyranoside nearly eliminating the hCD45+ MV-4-11

nearly eliminating the hCD45+ MV-4-11 cells at the 75 mg/kg dose in the blood (mean

InChiKey: BBAOKSZCULLDIW-UHFFFAOYSA-N

3-CETC is a fluorescent CYP1A1 &1A2 substrate

3)4)55-41(58)15-18-63-20-19-62-16-7-6-8-17-64-40-23-34-37(24-39(40)61-5)51-27-52-44(34)54-32-13-14-36(49)35(48)21-32/h9-14

is a potent and highly selective β1-adrenoceptor agonist

hVEGF-IN-1 ol-7-O-β-D-glucopyranoside nearly eliminating the hCD45+ MV-4-11hVEGF IN 1, a quinazoline derivative, could specifically bind to the G rich sequence in the internal ribosome entry site A (IRES A) and destabilize the G quadruplex structure. hVEGF IN 1 binds to the IRES A (WT) with a Kd of 0. 928 M in SPR experiments. hVEGF IN 1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF A protein expression. Product information CAS Number: 1637443 98 1 Molecular Weight: 581. 75 Formula: